论文部分内容阅读
目的研究低分子肝素注射液在肺性脑病治疗中的临床意义。方法将60例肺性脑病患者随机分为两组,治疗组(低分子肝素组)与对照组(非低分子肝素组)各30例,两组均给予常规治疗,治疗组除常规治疗外,加用低分子肝素,观察两组治疗前后意识、血气分析(PO2,PCO2)、血液流变学变化。结果治疗组显效22例,有效5例,无效3例。对照组13例,有效8例,无效9例,两组差别有显著性。结论治疗组意识恢复快,血气及血流变指标改善更明显。证明低分子肝素对肺性脑病有较好的辅助治疗价值。
Objective To study the clinical significance of low molecular weight heparin injection in the treatment of pulmonary encephalopathy. Methods Sixty patients with pulmonary encephalopathy were randomly divided into two groups. The treatment group (low molecular weight heparin group) and the control group (non-low molecular weight heparin group) each 30 patients. Both groups were given routine treatment. In addition to conventional treatment, Add low molecular weight heparin, observe the two groups before and after treatment awareness, blood gas analysis (PO2, PCO2), hemorheology changes. Results The treatment group markedly effective in 22 cases, effective in 5 cases, 3 cases. The control group of 13 cases, 8 cases were effective, 9 cases were ineffective, the difference between the two groups was significant. Conclusion The recovery of consciousness in the treatment group is quick, and the improvement of blood gas and blood rheology indexes is more obvious. Proved low molecular weight heparin on pulmonary encephalopathy have a better adjuvant therapy value.